Kiora Pharmaceuticals, Inc.
KPRX
$2.50
-$0.08-3.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -99.88% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -99.88% | -- |
| Cost of Revenue | -24.15% | -22.94% | -13.71% | -21.91% | 21.60% |
| Gross Profit | -133.39% | -133.25% | -134.73% | -136.17% | 376.21% |
| SG&A Expenses | 3.66% | 10.16% | 8.19% | 22.29% | 18.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.39% | -5.94% | -2.16% | -0.70% | 20.13% |
| Operating Income | -269.50% | -253.17% | -251.27% | -255.51% | 164.22% |
| Income Before Tax | -314.09% | -226.05% | -401.07% | -440.33% | 145.56% |
| Income Tax Expenses | -162.09% | 1,486.71% | 2,198.89% | 2,323.03% | 2,186.82% |
| Earnings from Continuing Operations | -401.41% | -253.92% | -474.44% | -529.20% | 128.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -401.41% | -253.92% | -474.44% | -529.20% | 128.73% |
| EBIT | -269.50% | -253.17% | -251.27% | -255.51% | 164.22% |
| EBITDA | -268.47% | -252.30% | -250.35% | -254.12% | 164.83% |
| EPS Basic | -212.54% | -435.74% | 56.16% | 78.25% | 108.65% |
| Normalized Basic EPS | -167.89% | -272.63% | -64.72% | 73.32% | 115.34% |
| EPS Diluted | -334.52% | -243.37% | 62.99% | 80.08% | 104.15% |
| Normalized Diluted EPS | -211.08% | -2,883.50% | 16.97% | 77.03% | 109.34% |
| Average Basic Shares Outstanding | 7.62% | 38.09% | 91.74% | 245.18% | 604.44% |
| Average Diluted Shares Outstanding | 1.47% | 28.01% | 71.75% | 185.93% | 650.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |